Andrew Zambanini, M.D.

Atopix Therapeutics, Chief Medical Officer

Clinical Development Consultant to Annapurna Therapeutics, Adverum Biotechnologies, Circassia, Theracos, Ferrumax, Kyowa Hakko Kirin, GSK, and Novartis

Vice-President and Medicine Development Leader (diabetes, immunoinflammation), GSK

Cardiovascular Clinical Head (Europe), GSK

Research Fellow in Clinical Pharmacology, Imperial College, London, UK

Research Fellow in Cardiology, Green Lane Hospital, Auckland, New Zealand

Licensed UK physician (St. George’s Hospital Medical School)

Dual board certified UK specialist in Clinical Pharmacology and Pharmaceutical Medicine

Member of the Royal College of Physicians of London

Fellow of the Faculty of Pharmaceutical Medicine, London